A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors. A Phase 1, Open-Label, Dose Escalation and Expansion Study of PF-06801591 in Patients With Locally Advanced or Metastatic Melanoma, Squamous Cell Head and Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Category & Conditions:
Cancer
Medicine:
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B8011001
Open Plain Language Summary Result:Click here